YHYue He

Yue He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yue He has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Ji

    Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, China

    3 shared publications
  • Yue He

    Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, China

    3 shared publications
  • Yumei Wu

    Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China

    3 shared publications
  • Jiandong Wang

    Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China

    2 shared publications
  • Chong Zhang

    Department of Gynecological Oncology Beijing Obstetrics and Gynecology Hospital, Capital Medical University Beijing China

    1 shared publication
  • Chun-Lin Pan

    Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China

    1 shared publication

Latest Publications

  • Inflammatory Markers and Advanced Lung Cancer Inflammation Index Predict Recurrence Patterns in Endometrial Cancer: A Retrospective Cohort Study

    by Rui Kong, Huimin Liu, Chong Zhang, Yumei Wu, Wei Xia, Qingfang Li, Zhiqi Wang

    Background: Systemic inflammatory and host‐related markers have demonstrated prognostic utility across multiple malignancies; however, their specific role in predicting recurrence patterns in endometrial cancer remains inadequately characterized. Notably, the Advanced Lung Cancer Inflammation Index (ALI), a novel host‐related biomarker, has not yet been evaluated in this context. Methods: We retrospectively analyzed 687 patients with endometrial cancer treated between 2010 and 2020. Pretreatment inflammatory markers, including the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), lymphocyte‐to‐monocyte ratio (LMR), neutrophil percentage‐to‐albumin ratio (NPAR), and ALI, were calculated based on routine laboratory data. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut‐off values for these markers. Multivariate logistic regression and multinomial regression were employed to assess predictors of recurrence and recurrence patterns, respectively. The C‐index was used to evaluate the discriminative ability of the prediction models. Results: Over a median 52‐month follow‐up, 127 patients (18.5%) recurred. Optimal cut‐offs: NLR > 2.45, PLR > 158, LMR ≤ 3.85, NPAR > 11.2, ALI ≤ 45.6. Multivariate analysis identified NLR (OR = 2.18), PLR (OR = 1.67), LMR (OR = 1.75), and ALI (OR = 2.42) as independent predictors (all p < 0.008). NLR was more predictive in early‐stage disease (interaction p = 0.032). Distinct patterns emerged: NLR predicted distant recurrence (RRR = 3.12), PLR was associated with local recurrence (RRR = 2.03), and ALI was associated with recurrence across all sites (local RRR = 1.82; regional RRR = 2.21; distant RRR = 3.45). The host‐related biomarker model demonstrated superior discrimination (C‐index = 0.821) versus FIGO staging alone (0.718, p < 0.001). Conclusions: Pre‐treatment inflammatory markers independently predict endometrial cancer recurrence with distinct site‐specific patterns. ALI is a promising composite host‐related biomarker that significantly improves risk stratification, offering a foundation for the design of prospective studies of personalized surveillance strategies.

  • Open Access

    Mechanism-Driven Evolution of Fertility-Sparing Treatment and Precision Management of Special Populations in Endometrial Cancer: A Review

    by Kai-Bing Qu, Chun-Lin Pan, Ming-Yue Zhang, Zhuo-Ying Du, Sheng-Qian Wang, Shu-Li Yang, Yu-Mei Wu, Jian-Dong Wang, Yue He

    Endometrial cancer is increasingly diagnosed in patients who have not yet completed childbearing. For carefully selected patients with grade 1 endometrioid endometrial carcinoma confined to the endometrium, fertility-sparing treatment (FST) can preserve reproductive potential but requires rigorous histologic surveillance. In eligible patients, oral progestins and/or the levonorgestrel-releasing intrauterine system (LNG-IUS) remain the mainstay of fertility-sparing treatment, with hysteroscopic lesion resection incorporated in selected cases. Obesity, polycystic ovary syndrome, abnormalities in glucose metabolism, molecular subtype, and primary or acquired progestin resistance collectively contribute to heterogeneity in treatment response and the risk of recurrence. This narrative review critically integrates current guidelines, randomized controlled trials, prospective studies, retrospective cohorts, and early exploratory evidence to evaluate the biological rationale, clinical positioning, efficacy, safety, and maturity of evidence for progestin-based therapy, metabolic interventions, combined endocrine approaches, molecularly guided strategies, and exploratory immunotherapeutic approaches. We further propose an integrated clinical pathway encompassing candidate selection, molecular assessment, response evaluation, transition to pregnancy, retreatment after recurrence, and timely conversion to definitive surgery. Importantly, this review distinguishes guideline-supported approaches from adjunctive, investigational, and exploratory strategies. Major evidence gaps include inconsistent definitions of treatment response, limited prospective molecularly stratified data, uncertain reproductive safety of emerging systemic therapies, and insufficient long-term data on pregnancy outcomes and offspring.

  • Open Access

    Comparison of the Efficacy of Polyvinyl Alcohol Colorless Embolic Microspheres (8Spheres) and Gelatin Embolic Microspheres (Embosphere) in Uterine Artery Embolization for Symptomatic Uterine Fibroids in Women Without Fertility Requirements: A Multicenter Observational Study

    by Songkun Gao, Fengshuang Li, Fang Song, Xiaofeng Zhang, Yan Wang, Jiandong Wang

    Objective: To evaluate the differences in efficacy between polyvinyl alcohol colorless embolic microspheres (8Spheres®) and gelatin embolic microspheres (Embosphere®) in uterine artery embolization for symptomatic uterine fibroids. Methods: We included 259 patients from 12 hospitals who underwent uterine artery embolization for symptomatic uterine fibroids. We collected preoperative general conditions, menstrual status, and uterine and fibroid sizes as indicated by magnetic resonance imaging, as well as changes in ovarian hormone levels before and 6 months after the procedure. Differences in uterine fibroid scores and health-related quality of life scores between the two types of microspheres were compared using analysis of covariance (ANCOVA). Differences in the largest fibroid volume, uterine volume, total menstrual bleeding score, and ovarian hormone levels were compared using T-tests or Mann–Whitney U-tests. Results: There was no significant difference in clinical efficacy between the two types of microspheres at 6 months postoperatively (P=0.4081). No significant differences were observed in uterine fibroid volume or symptom-related scores.There were no significant differences in ovarian hormone levels between the two groups or within each group before and after the procedure. Conclusion: The use of 8Spheres® is effective for symptomatic uterine fibroids and is comparable to the currently clinically used Embosphere® microspheres in terms of efficacy for symptomatic uterine fibroids.


  • Open Access

    Examination of the functions and mechanism of KCP in mediating paclitaxel resistance in cervical squamous carcinoma cells

    by Yue He, Jian-Qing Xu, Jing-Jing Zhang, Zhen-You Liu, Chen Ji, Yang Liu, Yun-Fan Wang, Ming Wang, Yu-Mei Wu, Yan Wang

    Objective: To evaluate the mechanism of Kielin/chordin-like protein (KCP) in the resistance of cervical cancer cells to paclitaxel.Method: A cervical squamous carcinoma cell line (SiHa) with KCP knockout was constructed and treated with paclitaxel. Key cell functions were assessed by colony formation assay, measurement of cell proliferation by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and FACS-based detection of apoptosis. The downstream mechanism of KCP-mediated resistance to paclitaxel was then examined using human gene chip detection and IPA bioinformatics analysis, and qPCR analysis was used to validate its downstream genes.Results: ①Functional studies of SiHa cells showed that KCP knockout (sgRNA) inhibited colony formation and proliferation of SiHa cells in the presence of paclitaxel (pKCP knockout versus the NC SiHa cells. IPA-based bioinformatics analysis of upstream regulators showed that SPI1 was strongly activated and that SPI1 inhibited CCND1 and activated PML and CEBPA, which is consistent with results from gene chip analysis showing CCND1, PML, and CEBPA expression after KCP knockout. ③A total of 30 differentially expressed genes associated with tumor cell proliferation were identified by gene microarray and IPA analyses. The changes in the aforementioned genes after KCP knockout were verified by qPCR, and SERPINB3 and CEBPA expression were significantly lower and higher, respectively, compared to in the control group.Conclusion: KCP increased resistance of cervical cancer to paclitaxel by enhancing cell proliferation and colony formation. We observed that KCP could act positively on the downstream gene SERPINB3 and negatively on the downstream gene CEBPA to affect the resistance of cervical carcinoma cells to paclitaxel.


  • Open Access

    Identification of necroptosis subtypes and development of necroptosis-related risk score model for in ovarian cancer

    by Chen Ji, Yue He, Yan Wang

    Background: ith the ongoing development of targeted therapy, non-apoptotic cell death, including necroptosis, has become a popular topic in the field of prevention and treatment. The purpose of this study was to explore the effect of necroptosis-related genes (NRGs) on the classification of ovarian cancer (OV) subtypes and to develop a necroptosis-related risk score (NRRS) classification system.Methods: 74 NRGs were obtained from the published studies, and univariate COX regression analysis was carried out between them and OV survival. Consensus clustering analysis was performed on OV samples according to the expression of NRGs related to prognosis. Furthermore, the NRRS model was developed by combining Weighted Gene Co-Expression Network Analysis (WGCNA) with least absolute shrinkage and selection operator (Lasso)-penalized Cox regression and multivariate Cox regression analysis. And the decision tree model was constructed based on the principle of random forest screening factors principle.Results: According to the post-related NRGs, OV was divided into two necroptosis subtypes. Compared with Cluster 1 (C1), the overall survival (OS) of Cluster 2 (C2) was significantly shorter, stromal score and immune score, the infiltration level of tumor associated immune cells and the expression of 20 immune checkpoints were significantly higher. WGCNA identified the blue module most related to necroptosis subtype, and 12 genes in the module were used to construct NRRS. NRRS was an independent prognostic variable of OV. The OS of samples with lower NRRS was significantly longer, and tumor mutation burden and homologous recombination defect were more obvious.Conclusion: This study showed that necroptosis plays an important role in the classification, prognosis, immune infiltration and biological characteristics of OV subtypes. The evaluation of tumor necroptosis may provide a new perspective for OV treatment.


  • Open Access

    Rethinking ovary preservation by adnexal torsion reversal in adolescents: a case of delayed diagnosis

    by Yue He, Chen Ji, Xiao-Chang Shen, Ke-Xin Zhang, Yu-Mei Wu, Yan Wang

    Background: This article discusses the management of an adolescent woman with a delayed diagnosis of adnexal torsion (AT) whose ovaries were successfully preserved. Case presentation: The patient was a 14-year-old female teen admitted with the chief complaint of lower abdominal pain for 3 days and worsening pain for 2 days. Magnetic resonance imaging suggested a high possibility of torsion in the anterosuperior uterine mass and was accompanied by severe ovarian edema, bleeding, and enlargement. Intraoperatively, the left fallopian tube was characterized by thickening and torsion and appeared blackish purple. The left fallopian tube paraovarian cyst was about 20 cm in size, and the left adnexa was twisted 1080° along the left infundibulopelvic ligament (suspensory ligament of the left ovary). The left ovary appeared blackish purple, with an enlarged diameter of about 10 cm. At the request and with the informed consent of the patient’s parents, we preserved the left ovary and removed the left fallopian tube. The results of the endocrine, ultrasound, and tumor marker tests were normal 1 month after surgery. Follicles and blood flow signals seen in ultrasound examinations indirectly proved the successful preservation of the left ovary in the follow-up. Conclusions: Our attempt to preserve the ovaries in an adolescent with a delayed diagnosis of AT was successful.


  • Open Access

    Quantitative analysis of proteins related to chemoresistance to paclitaxel and carboplatin in human SiHa cervical cancer cells via iTRAQ

    by Yue He, Su-Bin Han, Yu-Ning Geng, Shu-Li Yang, Yu-Mei Wu

    He Y, et al. J Gynecol Oncol. 2019 Jun;31:e28. https://doi.org/10.3802/jgo.2020.31.e28